Table 2.

Demographic and clinical characteristics of patients with CKD exclusively followed in primary care stratified for CKD stage

Class of DrugsOverall (n=30,326)CKD StageP Value
1 (n=904)2 (n=3142)3a (n=19,561)3b (n=5341)4 (n=1083)5 (n=295)
Antihypertensive dugs (N)1 (1–2)1 (0–2)1 (0–2)1 (0–2)2 (1–3)2 (1–3)2 (0–3)<0.001
RAS inhibitors (%)55.54554.752.866.264.844.1<0.001
Calcium channel blockers (%)25.820.525.52529.11913.2<0.001
β-Blockers (%)1812.716.818.318.51817.6<0.001
Thiazide diuretics (%)24.612.420.72.55.88.89.8<0.001
Loop diuretics (%)14.14.8810.824.943.329.5<0.001
Other (%)29.813.722.327.939.548.732.2<0.001
Antithrombotic drugs (%)36.325.434.73445.448.336.3<0.001
Lipid-lowering drugs (%)19.117.820.118.819.919.116.90.18
Nitrates (%)11.84.87.62429.839.740.3<0.001
Insulin (%)3.98.85.911.916.114.911.2<0.001
Oral hypogycemic agents (%)15.536.531.210.417.725.917.3<0.001
  • Data are percent or median (interquartile range). RAS, renin-angiotensin system.